Diffusion Pharmaceuticals, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2001-01-01
- Employees
- 13
- Market Cap
- -
Study of Trans Sodium Crocetinate in Patients With Interstitial Lung Disease
- Conditions
- Interstitial Lung Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-10-15
- Last Posted Date
- 2022-08-10
- Lead Sponsor
- Diffusion Pharmaceuticals Inc
- Target Recruit Count
- 18
- Registration Number
- NCT05079126
- Locations
- 🇺🇸
Pulmonary Associates, P.A., Phoenix, Arizona, United States
Randomized, Double-Blind, Placebo-Controlled, Crossover Study of Trans Sodium Crocetinate in Healthy Volunteers Exercising at Altitude
- Conditions
- Healthy Volunteers With Induced Hypoxia
- Interventions
- First Posted Date
- 2021-09-08
- Last Posted Date
- 2022-04-13
- Lead Sponsor
- Diffusion Pharmaceuticals Inc
- Target Recruit Count
- 30
- Registration Number
- NCT05036980
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
Safety and Efficacy of Trans Sodium Crocetinate (TSC) in Enhancing Tissue Oxygen Levels in Healthy Volunteers
- First Posted Date
- 2021-03-22
- Last Posted Date
- 2023-07-11
- Lead Sponsor
- Diffusion Pharmaceuticals Inc
- Target Recruit Count
- 30
- Registration Number
- NCT04808622
- Locations
- 🇺🇸
Altasciences Clinical Kansas Inc, Overland Park, Kansas, United States
Safety and Efficacy of Trans Sodium Crocetinate (TSC) in SARS-CoV-2 (COVID-19) Infected Subjects
- Conditions
- SARS-CoV-2 (Covid19)
- Interventions
- Drug: Normal saline
- First Posted Date
- 2020-10-05
- Last Posted Date
- 2022-04-14
- Lead Sponsor
- Diffusion Pharmaceuticals Inc
- Target Recruit Count
- 25
- Registration Number
- NCT04573322
- Locations
- 🇷🇴
National Institute of Infectious Diseases- Prof. Dr. Matei Balş, Bucharest, Romania
Efficacy and Safety of Trans Sodium Crocetinate (TSC) for Treatment of Suspected Stroke
- First Posted Date
- 2018-12-04
- Last Posted Date
- 2021-06-18
- Lead Sponsor
- Diffusion Pharmaceuticals Inc
- Target Recruit Count
- 6
- Registration Number
- NCT03763929
- Locations
- 🇺🇸
University of California, Los Angeles, Los Angeles, California, United States
🇺🇸University of Virginia, Charlottesville, Virginia, United States
Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects
- Conditions
- Glioblastoma
- Interventions
- Drug: Trans Sodium Crocetinate plus SOCOther: Standard of Care (SOC)
- First Posted Date
- 2018-01-08
- Last Posted Date
- 2021-07-22
- Lead Sponsor
- Diffusion Pharmaceuticals Inc
- Target Recruit Count
- 19
- Registration Number
- NCT03393000
- Locations
- 🇺🇸
UNM Comprehensive Cancer Center, Albuquerque, New Mexico, United States
🇺🇸John B. Amos Cancer Center, Columbus, Georgia, United States
🇺🇸Mount Sinai Hospital, New York, New York, United States
Safety and Efficacy of Trans Sodium Crocetinate (TSC) With Radiation and Temozolomide in Newly Diagnosed Glioblastoma
- Conditions
- GlioblastomaGliomaGBM
- Interventions
- Drug: Trans Sodium Crocetinate (TSC)
- First Posted Date
- 2011-11-04
- Last Posted Date
- 2017-07-14
- Lead Sponsor
- Diffusion Pharmaceuticals Inc
- Target Recruit Count
- 59
- Registration Number
- NCT01465347
- Locations
- 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸University of Florida McKnight Brain Institute, Gainesville, Florida, United States
🇺🇸Emory University Winship Cancer Institute, Atlanta, Georgia, United States
Trans Sodium Crocetinate (TSC) Study of Intra-tumoral Oxygen Concentration, Safety, and Pharmacokinetics in Patients With High Grade Glioma
- Conditions
- High Grade Glioma
- Interventions
- Drug: Trans Sodium Crocetinate (TSC)
- First Posted Date
- 2009-01-22
- Last Posted Date
- 2010-08-12
- Lead Sponsor
- Diffusion Pharmaceuticals Inc
- Target Recruit Count
- 1
- Registration Number
- NCT00826930
- Locations
- 🇺🇸
Johns Hopkins Medical Institute/Johns Hopkins Hospital, Baltimore, Maryland, United States
Safety, Efficacy, and Pharmacokinetics (PK) Study of Trans Sodium Crocetinate (TSC) in Patients With Intermittent Claudication
- Conditions
- Intermittent Claudication
- Interventions
- Drug: Trans sodium crocetinate (TSC)Drug: 0.9% normal saline
- First Posted Date
- 2008-07-31
- Last Posted Date
- 2011-07-29
- Lead Sponsor
- Diffusion Pharmaceuticals Inc
- Target Recruit Count
- 48
- Registration Number
- NCT00725881
- Locations
- 🇺🇸
Cardiology, P.C., Birmingham, Alabama, United States
🇺🇸Stanford University School of Medicine, Division of Cardiovascular Medicine, Stanford, California, United States
🇺🇸Andrews Research and Education, Pensacola, Florida, United States